Published on 2 May 2024 on Zacks via Yahoo Finance
Moderna, Inc. MRNA reported earnings of $3.07 per share in the first quarter of 2024, beating the Zacks Consensus Estimate of a loss of $3.59. In the year-ago period, management posted earnings of 19 cents per share. This bottom-line downtick was due to lower product sales during the quarter.
Revenues in the quarter were $167 million, beating the Zacks Consensus Estimate of $124.7 million. Total revenues declined 91% year over year due to reduced COVID-19 vaccine sales during the quarter.